oligonucleotide (Hybridon/Roche)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Nameoligonucleotide (Hybridon/Roche)
Drug Alias Nameoligonucleotide (Hybridon)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionDNA synthesis inhibitorsProtein synthesis inhibitorsVirus replication inhibitors
TargetsUpdating
Therapy Area/IndicationsHepatitis CHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerland
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAceragen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAceragen IncF. Hoffmann-La Roche Ltd
Active IndicationsN/A
Inactive IndicationsHepatitis CHepatitis B

Other Information

ATC CodeN/A
Related LinksN/A